Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Alexion (ALXN) Misses on Q1 Earnings and Revenues

Alexion Pharmaceuticals, Inc. ALXN focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this Cheshire, CT based company. In this scenario, investors focus should remain on Soliris performance.

Approval of Kanuma for the treatment of lysosomal acid lipase deficiency and Strensiq as long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease was a major boost to the company.

Alexion’s track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 2.10%, having beaten estimates in only one quarter and missing the same in the rest.

Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Alexion’s earnings missed expectations. Our consensus called for EPS of 91 cents, and the company reported EPS of 87 cents (these figures include stock-based compensation expense).

Revenue: Revenues were also below expectations. Alexion posted revenues of $701 million, compared to our consensus estimate of $712 million.

Key Stats: Soliris continues to drive revenues at Alexion. Strensiq and Kanuma sales are also picking up to global launches. The company revised its 2016 outlook. The company expects adjusted earnings per share to be at the lower end of $5.00 to $5.20 range. The company also expects revenues to be at the low end of $3.05–$3.1 billion. These revisions were made primarily due to increased unfavorable macroeconomic conditions in Latin America.

Check back later for our full write up on this Alexion earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ALEXION PHARMA (ALXN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.